PerkinElmer, Inc. (NYSE:PKI) insider Deborah A. Butters sold 7,414 shares of the business’s stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $98.00, for a total transaction of $726,572.00. Following the completion of the sale, the insider now directly owns 15,108 shares in the company, valued at approximately $1,480,584. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Shares of NYSE:PKI opened at $99.00 on Friday. PerkinElmer, Inc. has a 52 week low of $70.83 and a 52 week high of $99.42. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.16 and a current ratio of 1.60. The firm has a market capitalization of $10.85 billion, a PE ratio of 27.42, a PEG ratio of 2.13 and a beta of 1.25.
PerkinElmer (NYSE:PKI) last announced its earnings results on Thursday, January 31st. The medical research company reported $1.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.16 by $0.02. PerkinElmer had a net margin of 8.56% and a return on equity of 15.89%. The business had revenue of $756.35 million during the quarter, compared to analysts’ expectations of $746.15 million. During the same quarter last year, the company posted $0.97 EPS. On average, sell-side analysts forecast that PerkinElmer, Inc. will post 4.03 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 10th. Shareholders of record on Friday, April 19th will be paid a dividend of $0.07 per share. The ex-dividend date is Wednesday, April 17th. This represents a $0.28 annualized dividend and a yield of 0.28%. PerkinElmer’s dividend payout ratio is 7.76%.
PKI has been the subject of a number of recent research reports. Desjardins restated an “average” rating and issued a $45.00 price objective on shares of PerkinElmer in a research note on Wednesday, January 16th. Morgan Stanley decreased their target price on shares of PerkinElmer from $100.00 to $86.00 and set an “overweight” rating on the stock in a research report on Thursday, January 3rd. CIBC reissued an “average” rating and issued a $44.50 target price on shares of PerkinElmer in a research note on Thursday, January 10th. Piper Jaffray Companies increased their price target on shares of PerkinElmer to $104.00 and gave the stock an “overweight” rating in a research report on Friday, February 1st. Finally, Cowen reissued a “hold” rating and issued a $85.00 price target on shares of PerkinElmer in a research report on Sunday, January 6th. Nine research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. PerkinElmer presently has a consensus rating of “Hold” and a consensus target price of $82.76.
Several hedge funds and other institutional investors have recently bought and sold shares of PKI. Lindbrook Capital LLC bought a new stake in PerkinElmer during the 4th quarter worth approximately $25,000. Citizens Financial Group Inc RI acquired a new stake in PerkinElmer during the 4th quarter valued at $32,000. Penserra Capital Management LLC bought a new position in PerkinElmer in the 4th quarter valued at $35,000. Financial Gravity Companies Inc. bought a new position in PerkinElmer in the 4th quarter valued at $49,000. Finally, Karp Capital Management Corp acquired a new position in PerkinElmer in the fourth quarter worth $47,000. 96.39% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Insider Selling: PerkinElmer, Inc. (PKI) Insider Sells 7,414 Shares of Stock” was originally reported by Stock Observer and is the sole property of of Stock Observer. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.thestockobserver.com/2019/04/07/insider-selling-perkinelmer-inc-pki-insider-sells-7414-shares-of-stock.html.
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil.
Featured Article: What is dollar cost averaging (DCA)?
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.